Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.
Gelinck
L B S
LB
Teng
Y K O
YK
Rimmelzwaan
G F
GF
van den Bemt
B J F
BJ
Kroon
F P
FP
van Laar
J M
JM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology*; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007252:Influenza Vaccines; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab